Moderna and Merck Melanoma Vaccine Cuts Recurrence Risk by Forty-Two Percent

By Ed Silverman · STAT News · 2026-10-23

Moderna and Merck Melanoma Vaccine Cuts Recurrence Risk by Forty-Two Percent

STAT News reports that a personalized mRNA cancer treatment has significantly improved outcomes for melanoma patients in a large clinical trial. The data, which leaked ahead of its scheduled presentation at the European Society of Medical Oncology meeting, shows the vaccine outpe

STAT News reports that a personalized mRNA cancer treatment has significantly improved outcomes for melanoma patients in a large clinical trial. The data, which leaked ahead of its scheduled presentation at the European Society of Medical Oncology meeting, shows the vaccine outpe